 The FDA has issued a complete response letter CRL to Junshi Biosciences Co Ltd and Coherus BioSciences Incs NASDAQ: CHRS toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma NPC. NPC is a rare tumor of the head and neck. 